IMMP Soars 1,711% and IOVA Jumps 34% After EPS-Revision Signals
Immutep (IMMP) surged 1,711.5% to $4.71 since its September 27 EPS-revision screen, the standout gainer on this list, while Iovance Biotherapeutics (IOVA) climbed 33.8% to $14.45 after raising FY2026 revenue guidance to $410-$420 million on September 29. Smaller movers NNBR (+7.8%), LUXE (+4.7%) and RZLT (+3.8%) also delivered gains after their September 24 detections, with Rezolute reporting fiscal Q4 and full-year 2026 results showing $107.8 million in cash.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| IMMP | Healthcare | 2026-09-27 | N/A | +1711.5% |
| IOVA | Healthcare | 2026-09-24 | N/A | +33.8% |
| NNBR | Industrials | 2026-09-24 | +1.8pp | +7.8% |
| LUXE | Consumer Cyclical | 2026-09-24 | +162.6pp | +4.7% |
| RZLT | Healthcare | 2026-09-24 | N/A | +3.8% |
Why did IMMP stock jump in September 2026?
IMMP jumped 1,711.5% (from $0.26 to $4.71) after our screener flagged its next-year EPS growth estimate of 25.5% on September 27, 2026.
The move in the Immutep ADR came with no company-specific earnings news in the window, so the rally appears to reflect the market repricing a micro-cap biotech whose sub-$0.30 entry price left the stock highly sensitive to any fundamental signal. The screener caught the revision three days before the run date, and healthcare speculative names have been attracting outsized momentum flows when forward estimates turn positive.
IMMP EPS revision history → · Screener snapshot from 2026-09-27 →
FAQ: IMMP
Why did IMMP stock jump?
IMMP jumped 1,711.5% from $0.26 to $4.71 after our EPS revision screener flagged a 25.5% next-year growth estimate on September 27, 2026. No earnings-related news was found in the window, so the move pinned to speculative biotech squeeze dynamics.
Is IMMP a buy after its 1,711% rally?
IMMP's move came without company-specific news, which makes the rally speculative and heavily dependent on continued momentum in micro-cap healthcare. The 25.5% next-year EPS growth estimate supports the fundamental case, but the 1,711% gain implies a much higher risk profile now.
What is IMMP's EPS growth estimate?
Immutep's current next-year EPS growth estimate stood at 25.5% as of the September 27, 2026 screen date. The stock reflected that forecast by rallying to $4.71 by September 30.
Why did IOVA stock jump in September 2026?
IOVA jumped 33.8% (from $10.80 to $14.45) after our September 24 EPS screen flagged 52.0% next-year growth, and the move was confirmed September 29 when Iovance raised FY2026 revenue guidance to $410-$420 million.
The new midpoint of $415 million sits $55 million above the prior $350-$370 million range and clears the $402.8 million consensus analyst estimate, implying nearly 60% annual growth. Record Q2 product revenue of $99.3 million, driven by $89.5 million of Amtagvi and $9.8 million of Proleukin sales, gave management visibility into H2 2026. The rally lifted IOVA to a two-year high and marked a fourth monthly gain in five months, with the authorized treatment center network now approaching 100 locations.
IOVA EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: IOVA
Why did IOVA stock jump in September 2026?
IOVA jumped 33.8% from $10.80 to $14.45 after our September 24 EPS screen flagged 52.0% next-year growth and Iovance raised FY2026 revenue guidance to $410-$420 million on September 29. The revised $415 million midpoint cleared the $402.8 million consensus and implies nearly 60% annual growth.
Is IOVA a buy after its rally to two-year highs?
IOVA's 33.8% rally followed a $55 million midpoint guidance raise and record $99.3 million Q2 product revenue, giving it fundamental backing beyond momentum. Its nearly 100 authorized treatment centers and pipeline expansion into lung and endometrial cancers support further revenue visibility.
What is IOVA's EPS growth estimate?
Iovance's next-year EPS growth estimate was 52.0% when our screener detected the stock on September 24, 2026. That estimate accompanied the revenue guidance raise to $410-$420 million for FY2026.
Why did NNBR stock jump in September 2026?
NNBR rose 7.8% (from $3.60 to $3.88) after our September 24 screen showed its next-year EPS growth estimate revised from 71.0% to 72.7%.
No earnings-related news surfaced in the window, so the move tracked the broader industrial sector's momentum rather than a company catalyst. The 1.8-percentage-point upward revision is modest in absolute terms, and NN's price response reflected an orderly repricing rather than a headline-driven surge. The one-week hold from detection to run date suggests the market absorbed the estimate change without a news amplifier.
NNBR EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: NNBR
Why did NNBR stock rise in late September 2026?
NNBR climbed 7.8% from $3.60 to $3.88 after our September 24 screener flagged a next-year EPS growth revision from 71.0% to 72.7%. No company-specific earnings news was found in the window.
What is NNBR's next-year EPS growth estimate?
NN Inc's next-year EPS growth estimate was revised from 71.0% to 72.7%, a 1.8-percentage-point increase, when our screener detected it on September 24, 2026.
Is NNBR a buy after its EPS revision?
NNBR's 7.8% gain on a modest 1.8-point estimate revision suggests the move was sector-driven rather than news-driven. Without a company catalyst in the window, the case depends on whether industrials momentum continues.
Why did LUXE stock jump in September 2026?
LUXE rose 4.7% (from $9.18 to $9.61) after our September 24 screen showed its next-year EPS growth estimate revised from 2118.8% to 2281.3%, a 162.6-percentage-point increase.
The extraordinary magnitude reflects a recovery from a near-zero earnings base, so the revision is more a sign of directional improvement than a normalized growth rate. No earnings-related news appeared in the window, and the consumer-cyclical name moved in line with broader discretionary sentiment. The 4.7% price response to a triple-digit percentage-point revision is muted, suggesting the market treats the base-effect math cautiously.
LUXE EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: LUXE
Why did LUXE stock rise in late September 2026?
LUXE gained 4.7% from $9.18 to $9.61 after our September 24 screener flagged a next-year EPS growth revision from 2118.8% to 2281.3%. No earnings-related news was found in the detection-to-run window.
What is LUXE's EPS growth estimate?
LuxExperience's next-year EPS growth estimate was revised to 2281.3% from 2118.8%, a 162.6-percentage-point increase, at the September 24, 2026 detection. The figure reflects recovery from a near-zero earnings base.
Is LUXE a buy after its EPS estimate revision?
LUXE's 4.7% gain on a 162.6-point revision signals the market is discounting the base-effect math rather than treating it as a true growth signal. Without a news catalyst, the case rests on consumer-cyclical sector momentum.
Why did RZLT stock jump in September 2026?
RZLT gained 3.8% (from $3.94 to $4.09) after our September 24 EPS screen flagged 49.7% next-year growth, the same day Rezolute reported fiscal Q4 and full-year 2026 results.
The company disclosed $107.8 million in cash and investments as of June 30, 2026, with full-year R&D expenses falling to $53.8 million from $61.5 million a year earlier. The reduced spend, driven by lower ersodetug manufacturing costs, supports the runway narrative behind the 49.7% growth estimate. The modest 3.8% price response shows investors weighing the cash position against the absence of a near-term regulatory catalyst.
RZLT EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: RZLT
Why did RZLT stock rise in late September 2026?
RZLT rose 3.8% from $3.94 to $4.09 after our September 24 EPS screen flagged 49.7% next-year growth and Rezolute reported fiscal 2026 results with $107.8 million in cash. Full-year R&D expenses fell to $53.8 million from $61.5 million.
What is RZLT's EPS growth estimate?
Rezolute's next-year EPS growth estimate stood at 49.7% when our screener detected the stock on September 24, 2026. The same day, the company reported $107.8 million in cash and investments as of June 30, 2026.
Is RZLT a buy after its fiscal 2026 update?
RZLT's 3.8% gain came with a $107.8 million cash position and declining R&D spend of $53.8 million for fiscal 2026, supporting its runway. The 49.7% next-year EPS growth estimate depends on execution in its refractory hypoglycemia programs.
Today's screen shows the market rewarding healthcare biotechs with concrete commercial visibility (IOVA's guidance raise), speculative micro-caps with sharp price sensitivity (IMMP's 1,711% move), and industrials or consumer names on modest estimate revisions (NNBR, LUXE, RZLT). The dispersion suggests sector-specific momentum in healthcare is doing the heavy lifting, while non-healthcare names are seeing orderly repricing.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →